Try our beta test site
1334 studies found for:    Blood disorders AND Northwestern
Show Display Options
Rank Status Study
1 Not yet recruiting Ovarian Tissue Freezing For Fertility Preservation In Women Facing A Fertility Threatening Medical Diagnosis/Treatment
Conditions: Cancer;   Hematologic Disorder;   Rheumatologic Disorder;   Infertility
Intervention: Procedure: Ovarian Cryopreservation
2 Completed Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Conditions: Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Precancerous/Nonmalignant Condition;   Small Intestine Cancer
Interventions: Biological: anti-thymocyte globulin;   Biological: filgrastim;   Drug: cladribine;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: methylprednisolone;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: in vitro-treated peripheral blood stem cell transplantation
3 Unknown  Study of Allogeneic Bone Marrow and T-Cell Depleted, CD34+ Peripheral Blood Stem Cell Transplantation in Patients With Aplastic Anemia
Conditions: Graft Versus Host Disease;   Aplastic Anemia
Interventions: Drug: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: methylprednisolone;   Procedure: Allogeneic Bone Marrow Transplantation
4 Unknown  A Study of Co-infections of HIV-1 and Schistosoma Mansoni and Its Impact on Praziquantel Treatment Outcomes
Conditions: Anemia;   Intestinal Helminthiasis;   Intestinal Schistosomiasis;   Human Immunodeficiency Virus I Infection;   Hematologic Diseases;   Opportunistic Infections
Intervention: Drug: Praziquantel and Albendazole
5 Unknown  Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial
Conditions: Leukemia;   Lymphoma
Intervention: Other: biologic sample preservation procedure
6 Completed Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue
Conditions: Anemia;   Fatigue;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: epoetin alfa;   Procedure: physical therapy
7 Completed
Has Results
Platelet Count Trends in Pre-eclamptic Parturients
Conditions: Obstetric Labor Complications;   Preeclampsia;   Thrombocytopenia
Intervention:
8 Recruiting Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia
Conditions: Thrombocytopenia;   Cirrhosis
Intervention: Device: TheraSphere® Yttrium-90 Glass Microspheres, BTG International Inc.
9 Withdrawn Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
Conditions: Myelofibrosis;   Polycythemia Vera;   Primary Myelofibrosis;   Thrombocytopenia
Interventions: Procedure: Bone Marrow Aspiration and Biopsy;   Other: Laboratory Biomarker Analysis;   Biological: Siltuximab
10 Completed Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation
Conditions: Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes;   Biological: autologous Epstein-Barr virus-specific cytotoxic T lymphocytes
11 Terminated Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome
Condition: Myelodysplastic Syndromes
Intervention: Drug: sodium stibogluconate
12 Completed
Has Results
Coagulation Factor Changes Associated With Postpartum Hysterectomies
Conditions: Obstetric Labor Complications;   Hemorrhage;   Complications; Cesarean Section
Intervention: Procedure: Blood Draw
13 Recruiting Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
Conditions: Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase;   Primary Myelofibrosis
Interventions: Biological: Durvalumab;   Other: Laboratory Biomarker Analysis
14 Recruiting Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
Conditions: Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Epstein-Barr Virus Infection;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Progressive Hairy Cell Leukemia, Initial Treatment;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage IA Mycosis Fungoides/Sezary Syndrome;   Stage IB Mycosis Fungoides/Sezary Syndrome;   Stage II Adult Hodgkin Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IIA Mycosis Fungoides/Sezary Syndrome;   Stage IIB Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary Syndrome;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
Interventions: Drug: brentuximab vedotin;   Biological: rituximab;   Other: laboratory biomarker analysis
15 Recruiting Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia
Conditions: Acute Megakaryoblastic Leukemia;   Myelofibrosis;   Primary Myelofibrosis
Interventions: Drug: Alisertib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
16 Completed Using Differences in Peripheral Blood Leukocyte Gene Expression to Determine Cardiovascular Disease Risk
Conditions: Atherosclerosis;   Cardiovascular Diseases
Intervention:
17 Terminated Efficacy and Safety of Umbilical Cord Blood Injection for Critical Limb Ischemia
Condition: Critical Limb Ischemia
Intervention: Biological: Cord blood stem cell injection
18 Active, not recruiting Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Blastic Phase Chronic Myelogenous Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: metformin hydrochloride;   Drug: cytarabine;   Other: laboratory biomarker analysis
19 Completed
Has Results
Effects of Topical Vitamin K, Vitamin K and Retinol, and Arnica on Post-Laser Bruising
Condition: Ecchymosis
Interventions: Drug: Petrolatum United States Pharmacopeia (USP);   Drug: Vitamin K and retinol ointment;   Drug: Arnica ointment;   Drug: Vitamin K ointment
20 Completed The Effects of Iron and Omega-3 Fatty Acid Supplementation on Cognition and Immune Function in Iron Deficient Children
Conditions: Iron Deficiency;   Anemia
Interventions: Dietary Supplement: DHA and EPA Fish Oil capsule;   Dietary Supplement: Iron tablet;   Other: Placebo tablet;   Other: Placebo capsule

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.